ArticleJournal of biochemical and molecular toxicology2026
Dysregulation of the KLF9/TXNRD2 Axis Leads to Mitochondrial DNA Oxidation and NLRP3 Inflammasome Activation in Ulcerative Colitis.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study investigated the roles and mechanism of the transcription factor KLF9 and its downstream target gene TXNRD2 in ulcerative colitis (UC). An in vitro inflammatory model was established by stimulating human normal colonic mucosal epithelial cells (NCM460) with LPS and ATP. KLF9 or TXNRD2 expression was knocked down using RNA interference, and rescue experiments were performed using the NLRP3-specific agonist nigericin or by co-transfection with si-TXNRD2. A 3% DSS-induced UC model was established in C57BL/6 mice. Interventions were performed by tail vein injection of sh-KLF9 adeno-associated virus and/or intraperitoneal injection of nigericin. In DSS-induced UC mouse colon tissues and LPS/ATP-stimulated NCM460 cells, KLF9 was upregulated. KLF9 directly bound to the TXNRD2 promoter. Silencing KLF9 restored TXNRD2 expression, alleviated LPS/ATP-induced oxidative stress, decreased the accumulation of cytoplasmic ox-mtDNA and mtDNA, and inhibited NLRP3 inflammasome activation, as well as reduced pyroptosis, LDH release, and pro-inflammatory cytokine secretion. si-TXNRD2 or nigericin partially reversed the protective effects of KLF9 silencing. Colon-specific KLF9 knockdown improved DSS-induced weight loss, colonic shortening, disease activity index, and histopathological damage in mice, while simultaneously upregulating TXNRD2, inhibiting the NLRP3 pathway, and reducing oxidative stress and cytoplasmic mtDNA accumulation. Nigericin intervention partially offset the protective effects of KLF9 knockdown. KLF9 suppresses TXNRD2 transcription, leading to increased mitochondrial oxidative stress and the release of ox-mtDNA in intestinal epithelial cells, which in turn triggers NLRP3 inflammasome activation, driving pyroptosis and intestinal inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.